Aster DM Healthcare Q4 Revenue Climbs 18%, PAT Jumps 45% on Merger Momentum

Proforma Revenue (Aster+QCIL) ₹2,361 Cr | Proforma Operating EBITDA (Aster+QCIL) ₹517 Cr
Reader Takeaway: Strong results driven by operational gains; merger completion hinges on final regulatory nod.

What just happened

Aster DM Healthcare announced strong financial results for the fourth quarter of fiscal year 2026. The company posted an 18% year-on-year revenue growth, reaching ₹1,182 crore.

Operating EBITDA, excluding the Kasargod facility, saw a significant jump of 31% YoY to ₹253 crore, with improved margins. Normalized Profit After Tax (PAT) for the same segment also rose by 45% YoY to ₹153 crore.

Crucially, the proposed merger with Quality Care India Ltd (QCIL) received overwhelming shareholder support, with 96.68% of votes cast in favour. This marks a key step toward closing the transaction, which is expected in Q1 FY27.

The combined entity's proforma figures for Q4 FY26 reflect robust growth, with revenue up 18% to ₹2,361 crore and operating EBITDA increasing 25% to ₹517 crore.

Why this matters

This development signifies a major step for Aster DM Healthcare, positioning it to become one of India's top three healthcare providers. The merger with QCIL, backed by Blackstone, is set to create a larger, more integrated platform with enhanced scale and growth potential.

The strong quarterly performance shows the company's underlying operational strength, providing a solid foundation for the combined entity.

Shareholder approval is a key milestone, signalling confidence in the strategic rationale of the merger and the future prospects of the consolidated business.

The backstory

Aster DM Healthcare has been focusing on its Indian operations. Following the segregation of its GCC business in early 2024, the company has shifted its focus firmly to its Indian operations.

The merger with Quality Care India Ltd (QCIL), announced in November 2024, is a key part of this India-centric strategy. QCIL operates hospitals under the CARE Hospitals brand and is backed by Blackstone and TPG. It brings significant scale and presence, particularly in emerging cities.

The combined entity, to be named Aster DM Quality Care Ltd, is projected to manage around 38 hospitals with over 10,150 beds across 27 cities, operating under four major brands: Aster DM, CARE Hospitals, KIMSHEALTH, and Evercare.

The merger has already secured approval from the Competition Commission of India (CCI), indicating no adverse impact on market competition.

What changes now

Shareholders can anticipate a much larger and more diverse healthcare player in the Indian market.

The combined entity's enhanced scale is expected to drive operational efficiencies, cost synergies, and improved bargaining power.

Integration of QCIL's network, particularly its presence in emerging cities, could unlock new growth avenues for Aster.

The merger aims to solidify its position among the top three healthcare providers in India, potentially leading to greater market influence and investor interest.

Risks to watch

Proforma numbers for the merged entity are subject to finalization and audit of the combined accounts, and actual outcomes may differ from estimates.

The transaction's closing is contingent upon fulfilling remaining regulatory and compliance requirements, including the receipt of the final NCLT order.

Past allegations of employee misconduct, conflict of interest, and fraud at an Indian unit (Wahat Al Aman Home Healthcare), although not directly linked to the current operational performance, warrant continued scrutiny of governance practices.

Peer comparison

Aster DM Healthcare's merged entity aims to rival established giants like Apollo Hospitals and Max Healthcare.

Apollo Hospitals leads in FY25 revenue (₹21,794 Cr) and bed capacity (8,000+ beds), showcasing scale.

Max Healthcare, despite lower revenue, demonstrates superior operational efficiency with the highest ARPOB (₹2.84 Cr) and strong market capitalization, reflecting investor confidence in its profitability.

Fortis Healthcare also maintains a significant presence with over 6,000 beds and is recognized for its integrated healthcare services.

Narayana Hrudayalaya focuses on high-volume, affordable care, particularly in cardiac sciences, differentiating itself in the market.

What to track next

Monitor the final closure of the merger with Quality Care India Ltd by Q1 FY27.

Watch for the receipt of the NCLT order and other necessary regulatory approvals for transaction closure.

Observe post-merger integration progress and the operational and financial performance of the combined entity.

Track the company's ability to leverage the expanded network and achieve projected synergies.